company background image
A196170 logo

ALTEOGEN KOSDAQ:A196170 Stock Report

Last Price

₩277.00k

Market Cap

₩14.8t

7D

-10.8%

1Y

215.1%

Updated

23 Dec, 2024

Data

Company Financials +

A196170 Stock Overview

A bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. More details

A196170 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth6/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

ALTEOGEN Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for ALTEOGEN
Historical stock prices
Current Share Price₩277,000.00
52 Week High₩455,500.00
52 Week Low₩70,500.00
Beta1.22
1 Month Change-5.14%
3 Month Change-21.53%
1 Year Change215.13%
3 Year Change363.60%
5 Year Change1,390.58%
Change since IPO9,176.28%

Recent News & Updates

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

May 25
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Feb 29
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Recent updates

ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

May 25
ALTEOGEN's (KOSDAQ:196170) Shareholders Should Assess Earnings With Caution

ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Feb 29
ALTEOGEN (KOSDAQ:196170) Has Debt But No Earnings; Should You Worry?

Shareholder Returns

A196170KR BiotechsKR Market
7D-10.8%-3.9%-3.7%
1Y215.1%15.6%-10.4%

Return vs Industry: A196170 exceeded the KR Biotechs industry which returned 15.6% over the past year.

Return vs Market: A196170 exceeded the KR Market which returned -10.4% over the past year.

Price Volatility

Is A196170's price volatile compared to industry and market?
A196170 volatility
A196170 Average Weekly Movement11.8%
Biotechs Industry Average Movement8.7%
Market Average Movement6.6%
10% most volatile stocks in KR Market12.7%
10% least volatile stocks in KR Market3.3%

Stable Share Price: A196170's share price has been volatile over the past 3 months compared to the KR market.

Volatility Over Time: A196170's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
2008138Soon-Jae Parkwww.alteogen.com

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer.

ALTEOGEN Inc. Fundamentals Summary

How do ALTEOGEN's earnings and revenue compare to its market cap?
A196170 fundamental statistics
Market cap₩14.76t
Earnings (TTM)-₩2.91b
Revenue (TTM)₩74.38b

198.5x

P/S Ratio

-5,080x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A196170 income statement (TTM)
Revenue₩74.38b
Cost of Revenue₩42.23b
Gross Profit₩32.15b
Other Expenses₩35.05b
Earnings-₩2.91b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-54.53
Gross Margin43.22%
Net Profit Margin-3.91%
Debt/Equity Ratio4.3%

How did A196170 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 19:27
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALTEOGEN Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hyerin LeeDAOL Investment & Securities Co., Ltd.
null nullDBS Bank Ltd
Haesoon KwonEugene Investment & Securities Co Ltd.